December 2017—Aushon BioSystems and ABL announced that ABL has adopted the Cira platform for multiplex and ultrasensitive biomarker analysis. ABL will offer this proprietary technology as a new addition to its service offerings in support of pharmaceutical and clinical research clients.
Read More »